Erin Mistry
Corporate Officer/Principal bei CORMEDIX INC.
Vermögen: 55 167 $ am 31.03.2024
Aktive Positionen von Erin Mistry
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CORMEDIX INC. | Corporate Officer/Principal | 01.01.2020 | - |
Karriereverlauf von Erin Mistry
Ehemalige bekannte Positionen von Erin Mistry
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CORMEDIX INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Erin Mistry
- Erfahrung